Show simple item record

dc.contributor.authorBacila, I.
dc.contributor.authorFreeman, N.
dc.contributor.authorDaniel, E.
dc.contributor.authorSandrk, M.
dc.contributor.authorBryce, J.
dc.contributor.authorAli, S. R.
dc.contributor.authorYavas Abalı, Z.
dc.contributor.authorAtapattu, N.
dc.contributor.authorBachega, T. A.
dc.contributor.authorBalsamo, A.
dc.contributor.authorBirkebæk, N.
dc.contributor.authorBlankenstein, O.
dc.contributor.authorBonfig, W.
dc.contributor.authorCools, M.
dc.contributor.authorCosta, E. C.
dc.contributor.authorDarendeliler, F.
dc.contributor.authorEinaudi, S.
dc.contributor.authorElsedfy, H. H.
dc.contributor.authorFinken, M.
dc.contributor.authorGevers, E.
dc.contributor.authorClaahsen-van der Grinten, H. L.
dc.contributor.authorGuran, T.
dc.contributor.authorGüven, A.
dc.contributor.authorHannema, S. E.
dc.contributor.authorHigham, Claire E
dc.contributor.authorIotova, V.
dc.contributor.authorvan der Kamp, H. J.
dc.contributor.authorKorbonits, M.
dc.contributor.authorKrone, R. E.
dc.contributor.authorLichiardopol, C.
dc.contributor.authorLuczay, A.
dc.contributor.authorMendonca, B. B.
dc.contributor.authorMilenkovic, T.
dc.contributor.authorMiranda, M. C.
dc.contributor.authorMohnike, K.
dc.contributor.authorNeumann, U.
dc.contributor.authorOrtolano, R.
dc.contributor.authorPoyrazoglu, S.
dc.contributor.authorThankamony, A.
dc.contributor.authorTomlinson, J. W.
dc.contributor.authorVieites, A.
dc.contributor.authorde Vries, L.
dc.contributor.authorAhmed, S. F.
dc.contributor.authorRoss, R. J.
dc.contributor.authorKrone, N. P.
dc.date.accessioned2021-03-08T06:18:44Z
dc.date.available2021-03-08T06:18:44Z
dc.date.issued2021en
dc.identifier.citationBacila I, Freeman N, Daniel E, Sandrk M, Bryce J, Ali SR, et al. International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia - data from the I-CAH registry. Eur J Endocrinol. 2021.en
dc.identifier.pmid33460392en
dc.identifier.doi10.1530/eje-20-1249en
dc.identifier.urihttp://hdl.handle.net/10541/623773
dc.description.abstractObjective: Despite published guidelines no unified approach to hormone replacement in congenital adrenal hyperplasia (CAH) exists. We aimed to explore geographical and temporal variations in the treatment with glucocorticoids and mineralocorticoids in CAH. Design: This retrospective multi-center study, including 31 centers (16 countries), analyzed data from the International-CAH Registry. Methods: Data was collected from 461 patients aged 0-18 years with classic 21-hydroxylase deficiency (54.9% females) under follow-up between 1982 - 2018. Type, dose and timing of glucocorticoid and mineralocorticoid replacement was analyzed from 4174 patient visits. Results: The most frequently used glucocorticoid was hydrocortisone (87.6%). Overall, there were significant differences between age groups with regards to daily hydrocortisone-equivalent dose for body surface, with the lowest dose (median with interquartile range) of 12.0 (10.0 - 14.5) mg/ m2/ day at age 1 - 8 years and the highest dose of 14.0 (11.6 - 17.4) mg/ m2/ day at age 12-18 years. Glucocorticoid doses decreased after 2010 in patients 0-8 years (p<0.001) and remained unchanged in patients aged 8-18 years. Fludrocortisone was used in 92% of patients, with relative doses decreasing with age. A wide variation was observed among countries with regards to all aspects of steroid hormone replacement.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1530/eje-20-1249en
dc.titleInternational practice of corticosteroid replacement therapy in congenital adrenal hyperplasia - data from the I-CAH registryen
dc.typeArticleen
dc.contributor.departmentI Bacila, Oncology and Metabolism, The University of Sheffield, Sheffield, S10 2TNen
dc.identifier.journalEuropean Journal of Endocrinologyen
dc.description.noteen]
refterms.dateFOA2021-03-08T13:15:41Z


Files in this item

Thumbnail
Name:
33460392.pdf
Size:
1.890Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record